Advertisement

Topics

Drug Approvals Reports

13:37 EDT 19th August 2018 | BioPortfolio

Ovarian Cancer: Update Bulletin [January 2018] [Report Updated: 01012018] Prices from USD $1095

This edition presents key opinion leader KOL views on recent developments in the ovarian cancer market. Topics covered include: US Food and Drug Administration FDA acceptance for Genentech's supplemental Biologics License Application sBLA for Avastin bevacizumab and chemotherapy, followed by Avastin alone, in the frontline setting; EU approval of Zejula niraparib; Tesaro/Merck Co. for the treatme...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Drug Approvals market research data and corporate reports here